ASX-Dividend-Report-Banner

Complete Genomics integrates NVIDIA Parabricks to offer researchers faster, more cost-effective and accurate genomic sequencing analysis

October 30, 2024 12:00 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Complete Genomics integrates NVIDIA Parabricks to offer researchers faster, more cost-effective and accurate genomic sequencing analysis
Image source: Kalkine Media

Complete Genomics DNBSEQ data and NVIDIA Parabricks yield deeper insights into genetic variants with deep learning

SAN JOSE, Calif., Oct. 29, 2024 /PRNewswire/ -- Complete Genomics today announced an integration of its next-generation sequencing (NGS) DNBSEQ platforms* with NVIDIA Parabricks software for secondary analysis that will help researchers access accurate, faster and more affordable genomic analysis.

While NGS has transformed how researchers detect and analyze genetic variants, helping them provide critical insights into diseases like cancer, they still face challenges to accurately identify these variants amidst sequencing errors and genomic complexity.

With the latest features in Parabricks, including support for new data formats, enhanced variant calling, and integrated deep learning, researchers can achieve faster, more accurate results. This synergy not only accelerates the pace of discovery but also reduces costs, making high-throughput genomic analysis accessible for both research and clinical applications. By leveraging these advanced technologies, the path towards precision medicine becomes clearer, enabling deeper insights into the genetic foundations of disease and more targeted therapeutic strategies.

"Our integration of NVIDIA Parabricks allows us to harness the full potential of our DNBSEQ-T7 sequencing platform," said Rob Tarbox, VP of Product and Marketing at Complete Genomics. "By combining our high-quality sequencing data with Parabricks' speed and accuracy, we're enabling researchers to uncover variants more efficiently and cost-effectively, ultimately advancing precision medicine and improving patient outcomes," he said.

George Vacek, Global Head of Genomics Alliances at NVIDIA, added, "The combination of Parabricks software and Complete Genomics' sequencing technology creates a versatile and powerful tool for researchers, driving faster genomic analysis at lower costs and significantly accelerating scientific discovery across a variety of applications."

Complete Genomics' DNBSEQ technology brings low error rates, deep sequencing coverage, ideal for rare variants

Complete Genomics' DNBSEQ (DNA Nanoball Sequencing) technology is known for its high accuracy, low error rates, and capability to produce deep sequencing coverage. The DNBSEQ-T7 platform with its ultra-high throughput and exceptional data quality can generate up to 7 Tb of data per day, with a maximum read length of 150 bp paired-end reads and an accuracy rate of more than 99.9%. This high output and accuracy make it particularly well-suited for detecting rare variants and gaining comprehensive insights into complex landscapes.

NVIDIA Parabricks now supports a wider range of sequencing data formats, faster processing times, reduced computational costs

The latest release of NVIDIA Parabricks, a suite of GPU-accelerated genomic analysis tools that significantly enhance the speed, accuracy, and efficiency of NGS workflows, introduces several new features and improvements. In addition to supporting a wider range of sequencing data formats, including those specific to DNBSEQ, ensuring seamless integration with various sequencing technologies, Parabricks has updated versions of popular variant calling tools, such as GATK and DeepVariant, optimized for GPU acceleration. These tools have improved sensitivity and specificity, making them more effective in identifying low-frequency variants.

Parabricks also offers built-in support for deep learning models, enabling the rapid analysis of complex genomic data and the accurate distinction between true variants and sequencing errors. Importantly, the new Parabricks includes updated speed and cost benefits:

  • Faster Processing Times: By leveraging NVIDIA GPUs, Parabricks accelerates the entire genomic analysis pipeline. Using the DNBSEQ-T7 data, alignment tasks that typically take hours or days on traditional CPU-based systems can be completed in minutes. For example, aligning DNBSEQ-T7 reads to a reference genome is up to 50 times faster with Parabricks compared to traditional methods, significantly reducing time-to-insight.
    • Real-Time Analysis: The speed of Parabricks allows for near real-time analysis of large datasets, which is crucial for research and clinical applications where timely decisions can impact patient outcomes.
  • Reduced Computational Costs: The acceleration provided by GPUs means fewer computational resources are needed for each analysis, leading to lower costs. Researchers can process more data in less time without the need for extensive CPU infrastructure.
    • Scalability: Parabricks allows for scalable solutions that can handle large-scale genomic projects. This scalability means that even with increased data volumes from technologies like DNBSEQ-T7, the cost per sample remains extremely manageable, making high-throughput sequencing projects more economically viable.

About Complete Genomics

Complete Genomics is a pioneering life sciences company that provides novel, end to end DNA sequencing solutions. It has been at the forefront of high throughput cost-effective sequencing technology development since its inception in 2005. Our products have powered over 9,400 publications across a wide array of applications. To learn more, visit www.completegenomics.com.

*Complete Genomics' next-generation sequencing (NGS) DNBSEQ platforms as mentioned hereof, e.g. DNBSEQ-T7, are offered in the U.S. for research use only and not for use in any diagnostic procedures.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.